Latest news with #DavidJenkins
Yahoo
3 days ago
- General
- Yahoo
Why isn't an atom's nucleus round?
When you buy through links on our articles, Future and its syndication partners may earn a commission. Since the atomic nucleus was first proposed in 1911, physicists simply assumed it was round. But are the nuclei of atoms really round? Intuitively this shape makes sense and physicists believed it aptly explained early measurements of nuclear properties. It wasn't until years later that the first evidence of a more complex picture started to emerge. First, let's explore the atom's architecture. Formed from a cluster of protons and neutrons at the center of an atom, a nucleus is 10,000 times smaller than the atom as a whole, "like a fly in a cathedral," said David Jenkins, a nuclear physicist at the University of York in the U.K. Despite containing the overwhelming majority of an atom's mass, the nucleus itself has very little impact on the atom's properties at first glance. An atom's chemistry is determined by the electron configuration, while any physical characteristics arise from how it interacts with other atoms. Paralleling the idea of electron shells in atomic physics, in 1949 scientists proposed the nuclear shell model: protons and neutrons sit in distinct nuclear shells, and additional energy input can excite these particles to jump up and down between fixed energy levels. "But later, it became obvious that most of the behavior in nuclei was described by what you call collective behavior — it acts as one coherent object," Jenkins told Live Science. The result is that the nucleus as a whole can then manifest two types of properties: It can rotate, or it can vibrate. Related: Where do electrons get energy to spin around an atom's nucleus? Spectroscopic methods can detect this rotation in most molecules, measuring a fingerprint of different rotational energy levels. But spherical objects look the same whichever direction they are turned, so symmetrical systems — like atoms — don't generate a spectrum. "The only way that you can see evidence of rotation in nuclei is if the nucleus is deformed," Jenkins explained. "And people saw the nucleus has patterns of excitation known as rotational bands, so that pointed to the nucleus being deformed." Since this astonishing discovery in the 1950s, targeted experiments have revealed a raft of nuclear shapes, from pears to M&Ms — and round is very much the exception and not the rule. About 90% of nuclei are shaped like an American football — technically termed "prolate deformed" — in their lowest energy state, with surprisingly few taking the opposite squashed-sphere, M&M-like shape, called oblate deformed. "We don't know why this prolate shape seems more favorable than the oblate shape," Jenkins said. "Some nuclei also have multiple shapes so they can exhibit one in the ground state, and then you put some energy into them and they deform into another shape." The more exotic pear-shaped nucleus is restricted to certain areas of the nuclear chart, particularly around radium, while spherical nuclei are generally confined to atoms with "magic" numbers (or full shells) of nuclear particles. But what causes the deformation? "It feels intuitive that the basic shape of an object not being excited or wobbled or stretched should be spherical," said Paul Stevenson, a nuclear physicist at the University of Surrey in the U.K. "But actually, in the case of nuclei, it's surprising that any of them are spherical because they obey the laws of quantum mechanics." The Schrödinger equation — one of the most fundamental principles in quantum mechanics — mathematically predicts how an object's wave function will change over time, essentially providing a means to estimate the possible movement and position of that object. Solving this for an atomic nucleus therefore provides a cloud of probability for all of the possible places it could be, which, taken together, give the nuclear shape. RELATED MYSTERIES —What is the smallest particle in the universe? (What about the largest?) —How many atoms are in the observable universe? —Do atoms ever touch? "The basic solutions of Schrödinger's equation don't look spherical — you get these shapes that sort of go in a circle, but then they start waving," Stevenson explained. "So because these quantum wave-function solutions have asymmetry themselves, it makes the particles in the nucleus more likely to point in one direction." For rare spherical nuclei, this waviness just happens to cancel out. But scientists don't yet understand the reason — or if there even is one — why some of these deformed shapes are much more common than others. "This is overturning a legacy," Jenkins said. "It's a complete reversal from how people originally perceived nuclei, and there are still a lot of open questions."
Business Upturn
13-05-2025
- Business
- Business Upturn
Catheter Precision, Inc. Announces $1.5 Million Private Placement Equity Financing and Potential Strategic Alliance
Fort Mill, S.C., May 12, 2025 (GLOBE NEWSWIRE) — Catheter Precision (VTAK – NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announced that it has entered into securities purchase agreements with institutional investors for a $1.5 million private placement equity financing and the acquisition of certain promissory notes of QHSLab, Inc. David Jenkins, CEO of Catheter Precision, commented, 'We are pleased to have entered into these transactions. The transactions supply financial resources for our company, as well as the potential to work with another company to expand our reach into general cardiology and further our reach into cardiac electrophysiology with office-oriented product lines, extending the reach of our direct US sales force currently focused on our hospital oriented cardiac electrophysiology products.' Ladenburg Thalmann & Co. Inc. acted as exclusive placement agent for these transactions. In the funding portion of the transaction, in exchange for $1.5 million in cash, the Company sold 1,500 shares of its Series B Preferred Stock ('Preferred Stock') to the investors which are convertible into an aggregate of 4,287,000 shares of common stock of the Company, or 2,858 shares of common stock per share of preferred, and 4,285,716 Warrants to purchase the Company's common stock at an exercise price of $0.50 per share. The Warrants may be called by the company should the underlying common stock trade for $1.50 or more within a twenty consecutive day period while there is an effective registration statement. The Warrants have a five 1/2-year term from the date stockholder approval of their exercise is obtained. The Preferred Stock and Warrants issued in this transaction do not have any variable priced conversion features, price-based ratchets, or except in certain specified situations, alternative cashless exercise provisions, voting rights or pay a dividend. The substantial majority of the Preferred Stock, and 100% of the Warrants issued in the transaction are not convertible until an affirmative vote of the Company's shareholders. The Company also issued an additional 1,500 shares of its Series B Preferred Stock, which are convertible into an aggregate of 4,287,000 shares of common stock of the Company, or 2,858 shares of common stock per share of preferred, to acquire preexisting senior secured notes of QHSLabs held by one of the funds participating in the funding transaction. QHS operates in the marketplace of general physicians, family practice, cardiology, and cardiac electrophysiology, with products that assist the physician in diagnosing different health components including mental health, cardiology health, drug compliance, and various allergies analyses. We believe that the approximate aggregate principal amount, plus all accrued but unpaid, interest, fees and other amounts, owed by QHSLabs under the notes is equal to approximately $1.6 million; however, both notes are currently in default, there can be no assurance that they will be paid in full or at all, and their valuation is uncertain. The notes currently accrue default interest at 18%, and are convertible into QHSLab common stock, primarily at a rate of $0.20 per share. The Company and QHS are currently pursuing a strategic partnership within the cardiovascular space. See our Current Report on Form 8-K filed today for additional information regarding this transaction and the notes acquired. About Catheter Precision Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. Cautionary Note Regarding Forward-Looking Statements Cautionary Note Regarding Forward-Looking Statements This communication contains forward-looking statements. Forward-looking statements can be identified by words such as 'believe,' 'anticipate,' 'may,' 'might,' 'can,' 'could,' 'continue,' 'depends,' 'expect,' 'expand,' 'forecast,' 'intend,' 'predict,' 'plan,' 'rely,' 'should,' 'will,' 'may,' 'seek,' 'promising,' 'potential,' or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, but are not limited to, express and implied statements regarding the following: our expectations, our ability to collaborate with QHSLab, Inc., the potential expansion of the reach of our sales force, and the potential value or lack thereof of the notes acquired. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption 'Risk Factors' in the Company's 2024 Form 10-K filed with the SEC and available at These risks and uncertainties include, but aren't limited to: that we may be unable to successfully build a profitable collaboration with QHSLab and that our sales force may not be able to successfully sell into that product/service space, that the notes acquired from QHSLab are currently in default and have been for some time, and therefore QHSLab may be unable to pay any or all of the amounts owing under them, that although the notes are convertible into QHSLab common stock, that common stock is thinly traded and could be difficult to liquidate, and the conversion is subject to a 4.99% beneficial ownership blocker, that QHSLab has not agreed to our calculation of the total amounts outstanding under that notes, that our ability to develop and commercialize the CPNS System acquired from Cardionomic could be adversely impacted if we are unable to maintain protection of the patents and trade names related thereto, which we are acquiring on an as is basis without recourse; that we may not be able to obtain the financing for our Cardionomix subsidiary that we anticipate and/or such financing even if obtained may not be adequate for the development of the CPNS System; and that we may not adequately address the lessons learned from the Cardionomic pilot studies which included fatigue to nerves if stimulation is delivered for too long; high amplitude stimulation can lead to unstable hemodynamics, rhythm disturbances, and patient sensation; optimal stimulation response is dependent on more than just contractility; stimulation beyond 48 hours did not show additional benefit; stimulator modifications required to reduce procedure time, complexity, and improve user experience; and minor catheter modifications needed to accommodate larger anatomy in heart failure patients. FDA review of the CPNS System is likely to be costly and lengthy, and there is no guarantee that clearance and approval will ever occur or occur on a timetable that is beneficial to the Company. Additionally, the new subsidiary has other, minority investors aside from the Company, and future financings are expected to involve the issuance of securities by the subsidiary, which will reduce the Company's share in the profits, if any, from the CPNS System and the new subsidiary, and is likely to involve the grant of special corporate governance rights to other subsidiary investors so that the Company will not have unfettered control of the new subsidiary. There is no guarantee that the success of the pilot studies will be repeated in future trials or ultimately lead to a successful commercialization of the CPNS System. The medical device industry in general is highly competitive, and some of our competitors have longer, more established operating histories, with significantly greater financial, technical, marketing, sales, distribution, and other resources. The CPNS System is not the only device-based neuromodulation therapy currently in development for the treatment of heart failure and further must also compete against potential new drug therapies. In general, results of anticipated trials may not turn out as we currently expect, and future trials may not occur on the timetables we expect or may be more costly than anticipated. In addition, our forward looking statements are subject to the following additional uncertainties and risks: even with this recent financing, we do not have sufficient liquidity to fund our business unless we are able to obtain additional financing or enter into a strategic transaction that would provide additional liquidity during the next three to six months will not be able to reach profitability unless we are able to achieve our product expansion and growth goals, our research and development and commercialization efforts may depend on entering into agreements with corporate collaborators, we have in the past entered into joint marketing agreements with respect to our products, and may again enter into additional joint marketing agreements in the future that could reduce our revenues from product sales, if we experience significant disruptions in our information technology systems, our business may be adversely affected, litigation and other legal proceedings may adversely affect our business, if we make acquisitions or divestitures, we could encounter difficulties that harm our business, failure to attract and retain sufficient qualified personnel could also impede our growth, failure to maintain effective internal controls could cause our investors to lose confidence in us and adversely affect the market price of our common stock, we have determined that our internal controls and disclosure controls were not effective as of March 31, 2024, June 30, 2024, September 30, 2024, and December 31, 2024, and as a result, without effective remediation of the material weaknesses that we have identified, we may not be able to accurately report our financial results or prevent fraud, our revenues may depend on our customers' receipt of adequate reimbursement from private insurers and government sponsored healthcare programs, we may be unable to compete successfully with companies in our highly competitive industry, many of whom have substantially greater resources than we do, our future operating results depend upon our ability to obtain components in sufficient quantities on commercially reasonable terms or according to schedules, prices, quality and volumes that are acceptable to us, and suppliers may fail to deliver components, or we may be unable to manage these components effectively or obtain these components on such terms, if hospitals, physicians and patients do not accept our current and future products or if the market for indications for which any product candidate is approved is smaller than expected, we may be unable to generate significant revenue, if any, our medical device operations are subject to pervasive and continuing FDA regulatory requirements, our products may be subject to additional recalls, revocations or suspensions after receiving FDA or foreign approval or clearance, which could divert managerial and financial resources, harm our reputation, and adversely affect our business, changes in trade policies among the U.S. and other countries, in particular the imposition of new or higher tariffs by the U.S. and/or its trading partners could increase our expenses, require us to increase prices, potentially lowering demand for our products, and/or reduce our revenues and operating results, and such increase , or the imposition of other barriers to international trade, could have a material adverse effect on our revenues and operating results. The risks and uncertainties described above may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty, or other pandemics, supply chain disruptions from the Ukraine war or Israeli-Hamas conflict and otherwise, and ongoing volatility in the stock markets and the U.S. economy in general. The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law. CONTACTS: At the CompanyDavid Jenkins973-691-2000 [email protected]
Yahoo
13-05-2025
- Business
- Yahoo
Catheter Precision, Inc. Announces $1.5 Million Private Placement Equity Financing and Potential Strategic Alliance
Fort Mill, S.C., May 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announced that it has entered into securities purchase agreements with institutional investors for a $1.5 million private placement equity financing and the acquisition of certain promissory notes of QHSLab, Inc. David Jenkins, CEO of Catheter Precision, commented, "We are pleased to have entered into these transactions. The transactions supply financial resources for our company, as well as the potential to work with another company to expand our reach into general cardiology and further our reach into cardiac electrophysiology with office-oriented product lines, extending the reach of our direct US sales force currently focused on our hospital oriented cardiac electrophysiology products." Ladenburg Thalmann & Co. Inc. acted as exclusive placement agent for these transactions. In the funding portion of the transaction, in exchange for $1.5 million in cash, the Company sold 1,500 shares of its Series B Preferred Stock ('Preferred Stock') to the investors which are convertible into an aggregate of 4,287,000 shares of common stock of the Company, or 2,858 shares of common stock per share of preferred, and 4,285,716 Warrants to purchase the Company's common stock at an exercise price of $0.50 per share. The Warrants may be called by the company should the underlying common stock trade for $1.50 or more within a twenty consecutive day period while there is an effective registration statement. The Warrants have a five 1/2-year term from the date stockholder approval of their exercise is obtained. The Preferred Stock and Warrants issued in this transaction do not have any variable priced conversion features, price-based ratchets, or except in certain specified situations, alternative cashless exercise provisions, voting rights or pay a dividend. The substantial majority of the Preferred Stock, and 100% of the Warrants issued in the transaction are not convertible until an affirmative vote of the Company's shareholders. The Company also issued an additional 1,500 shares of its Series B Preferred Stock, which are convertible into an aggregate of 4,287,000 shares of common stock of the Company, or 2,858 shares of common stock per share of preferred, to acquire preexisting senior secured notes of QHSLabs held by one of the funds participating in the funding transaction. QHS operates in the marketplace of general physicians, family practice, cardiology, and cardiac electrophysiology, with products that assist the physician in diagnosing different health components including mental health, cardiology health, drug compliance, and various allergies analyses. We believe that the approximate aggregate principal amount, plus all accrued but unpaid, interest, fees and other amounts, owed by QHSLabs under the notes is equal to approximately $1.6 million; however, both notes are currently in default, there can be no assurance that they will be paid in full or at all, and their valuation is uncertain. The notes currently accrue default interest at 18%, and are convertible into QHSLab common stock, primarily at a rate of $0.20 per share. The Company and QHS are currently pursuing a strategic partnership within the cardiovascular space. See our Current Report on Form 8-K filed today for additional information regarding this transaction and the notes acquired. About Catheter PrecisionCatheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. Cautionary Note Regarding Forward-Looking Statements Cautionary Note Regarding Forward-Looking Statements This communication contains forward-looking statements. Forward-looking statements can be identified by words such as "believe," "anticipate," "may," "might," "can," "could," "continue," "depends," "expect," "expand," "forecast," "intend," "predict," "plan," "rely," "should," "will," "may," "seek," "promising," "potential," or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, but are not limited to, express and implied statements regarding the following: our expectations, our ability to collaborate with QHSLab, Inc., the potential expansion of the reach of our sales force, and the potential value or lack thereof of the notes acquired. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption "Risk Factors" in the Company's 2024 Form 10-K filed with the SEC and available at These risks and uncertainties include, but aren't limited to: that we may be unable to successfully build a profitable collaboration with QHSLab and that our sales force may not be able to successfully sell into that product/service space, that the notes acquired from QHSLab are currently in default and have been for some time, and therefore QHSLab may be unable to pay any or all of the amounts owing under them, that although the notes are convertible into QHSLab common stock, that common stock is thinly traded and could be difficult to liquidate, and the conversion is subject to a 4.99% beneficial ownership blocker, that QHSLab has not agreed to our calculation of the total amounts outstanding under that notes, that our ability to develop and commercialize the CPNS System acquired from Cardionomic could be adversely impacted if we are unable to maintain protection of the patents and trade names related thereto, which we are acquiring on an as is basis without recourse; that we may not be able to obtain the financing for our Cardionomix subsidiary that we anticipate and/or such financing even if obtained may not be adequate for the development of the CPNS System; and that we may not adequately address the lessons learned from the Cardionomic pilot studies which included fatigue to nerves if stimulation is delivered for too long; high amplitude stimulation can lead to unstable hemodynamics, rhythm disturbances, and patient sensation; optimal stimulation response is dependent on more than just contractility; stimulation beyond 48 hours did not show additional benefit; stimulator modifications required to reduce procedure time, complexity, and improve user experience; and minor catheter modifications needed to accommodate larger anatomy in heart failure patients. FDA review of the CPNS System is likely to be costly and lengthy, and there is no guarantee that clearance and approval will ever occur or occur on a timetable that is beneficial to the Company. Additionally, the new subsidiary has other, minority investors aside from the Company, and future financings are expected to involve the issuance of securities by the subsidiary, which will reduce the Company's share in the profits, if any, from the CPNS System and the new subsidiary, and is likely to involve the grant of special corporate governance rights to other subsidiary investors so that the Company will not have unfettered control of the new subsidiary. There is no guarantee that the success of the pilot studies will be repeated in future trials or ultimately lead to a successful commercialization of the CPNS System. The medical device industry in general is highly competitive, and some of our competitors have longer, more established operating histories, with significantly greater financial, technical, marketing, sales, distribution, and other resources. The CPNS System is not the only device-based neuromodulation therapy currently in development for the treatment of heart failure and further must also compete against potential new drug therapies. In general, results of anticipated trials may not turn out as we currently expect, and future trials may not occur on the timetables we expect or may be more costly than anticipated. In addition, our forward looking statements are subject to the following additional uncertainties and risks: even with this recent financing, we do not have sufficient liquidity to fund our business unless we are able to obtain additional financing or enter into a strategic transaction that would provide additional liquidity during the next three to six months will not be able to reach profitability unless we are able to achieve our product expansion and growth goals, our research and development and commercialization efforts may depend on entering into agreements with corporate collaborators, we have in the past entered into joint marketing agreements with respect to our products, and may again enter into additional joint marketing agreements in the future that could reduce our revenues from product sales, if we experience significant disruptions in our information technology systems, our business may be adversely affected, litigation and other legal proceedings may adversely affect our business, if we make acquisitions or divestitures, we could encounter difficulties that harm our business, failure to attract and retain sufficient qualified personnel could also impede our growth, failure to maintain effective internal controls could cause our investors to lose confidence in us and adversely affect the market price of our common stock, we have determined that our internal controls and disclosure controls were not effective as of March 31, 2024, June 30, 2024, September 30, 2024, and December 31, 2024, and as a result, without effective remediation of the material weaknesses that we have identified, we may not be able to accurately report our financial results or prevent fraud, our revenues may depend on our customers' receipt of adequate reimbursement from private insurers and government sponsored healthcare programs, we may be unable to compete successfully with companies in our highly competitive industry, many of whom have substantially greater resources than we do, our future operating results depend upon our ability to obtain components in sufficient quantities on commercially reasonable terms or according to schedules, prices, quality and volumes that are acceptable to us, and suppliers may fail to deliver components, or we may be unable to manage these components effectively or obtain these components on such terms, if hospitals, physicians and patients do not accept our current and future products or if the market for indications for which any product candidate is approved is smaller than expected, we may be unable to generate significant revenue, if any, our medical device operations are subject to pervasive and continuing FDA regulatory requirements, our products may be subject to additional recalls, revocations or suspensions after receiving FDA or foreign approval or clearance, which could divert managerial and financial resources, harm our reputation, and adversely affect our business, changes in trade policies among the U.S. and other countries, in particular the imposition of new or higher tariffs by the U.S. and/or its trading partners could increase our expenses, require us to increase prices, potentially lowering demand for our products, and/or reduce our revenues and operating results, and such increase , or the imposition of other barriers to international trade, could have a material adverse effect on our revenues and operating results. The risks and uncertainties described above may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty, or other pandemics, supply chain disruptions from the Ukraine war or Israeli-Hamas conflict and otherwise, and ongoing volatility in the stock markets and the U.S. economy in general. The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law. CONTACTS: At the CompanyDavid Jenkins973-691-2000info@ # # #
Yahoo
12-05-2025
- Business
- Yahoo
Catheter Precision, Inc. Announces $1.5 Million Private Placement Equity Financing and Potential Strategic Alliance
Fort Mill, S.C., May 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announced that it has entered into securities purchase agreements with institutional investors for a $1.5 million private placement equity financing and the acquisition of certain promissory notes of QHSLab, Inc. David Jenkins, CEO of Catheter Precision, commented, "We are pleased to have entered into these transactions. The transactions supply financial resources for our company, as well as the potential to work with another company to expand our reach into general cardiology and further our reach into cardiac electrophysiology with office-oriented product lines, extending the reach of our direct US sales force currently focused on our hospital oriented cardiac electrophysiology products." Ladenburg Thalmann & Co. Inc. acted as exclusive placement agent for these transactions. In the funding portion of the transaction, in exchange for $1.5 million in cash, the Company sold 1,500 shares of its Series B Preferred Stock ('Preferred Stock') to the investors which are convertible into an aggregate of 4,287,000 shares of common stock of the Company, or 2,858 shares of common stock per share of preferred, and 4,285,716 Warrants to purchase the Company's common stock at an exercise price of $0.50 per share. The Warrants may be called by the company should the underlying common stock trade for $1.50 or more within a twenty consecutive day period while there is an effective registration statement. The Warrants have a five 1/2-year term from the date stockholder approval of their exercise is obtained. The Preferred Stock and Warrants issued in this transaction do not have any variable priced conversion features, price-based ratchets, or except in certain specified situations, alternative cashless exercise provisions, voting rights or pay a dividend. The substantial majority of the Preferred Stock, and 100% of the Warrants issued in the transaction are not convertible until an affirmative vote of the Company's shareholders. The Company also issued an additional 1,500 shares of its Series B Preferred Stock, which are convertible into an aggregate of 4,287,000 shares of common stock of the Company, or 2,858 shares of common stock per share of preferred, to acquire preexisting senior secured notes of QHSLabs held by one of the funds participating in the funding transaction. QHS operates in the marketplace of general physicians, family practice, cardiology, and cardiac electrophysiology, with products that assist the physician in diagnosing different health components including mental health, cardiology health, drug compliance, and various allergies analyses. We believe that the approximate aggregate principal amount, plus all accrued but unpaid, interest, fees and other amounts, owed by QHSLabs under the notes is equal to approximately $1.6 million; however, both notes are currently in default, there can be no assurance that they will be paid in full or at all, and their valuation is uncertain. The notes currently accrue default interest at 18%, and are convertible into QHSLab common stock, primarily at a rate of $0.20 per share. The Company and QHS are currently pursuing a strategic partnership within the cardiovascular space. See our Current Report on Form 8-K filed today for additional information regarding this transaction and the notes acquired. About Catheter PrecisionCatheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. Cautionary Note Regarding Forward-Looking Statements Cautionary Note Regarding Forward-Looking Statements This communication contains forward-looking statements. Forward-looking statements can be identified by words such as "believe," "anticipate," "may," "might," "can," "could," "continue," "depends," "expect," "expand," "forecast," "intend," "predict," "plan," "rely," "should," "will," "may," "seek," "promising," "potential," or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, but are not limited to, express and implied statements regarding the following: our expectations, our ability to collaborate with QHSLab, Inc., the potential expansion of the reach of our sales force, and the potential value or lack thereof of the notes acquired. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption "Risk Factors" in the Company's 2024 Form 10-K filed with the SEC and available at These risks and uncertainties include, but aren't limited to: that we may be unable to successfully build a profitable collaboration with QHSLab and that our sales force may not be able to successfully sell into that product/service space, that the notes acquired from QHSLab are currently in default and have been for some time, and therefore QHSLab may be unable to pay any or all of the amounts owing under them, that although the notes are convertible into QHSLab common stock, that common stock is thinly traded and could be difficult to liquidate, and the conversion is subject to a 4.99% beneficial ownership blocker, that QHSLab has not agreed to our calculation of the total amounts outstanding under that notes, that our ability to develop and commercialize the CPNS System acquired from Cardionomic could be adversely impacted if we are unable to maintain protection of the patents and trade names related thereto, which we are acquiring on an as is basis without recourse; that we may not be able to obtain the financing for our Cardionomix subsidiary that we anticipate and/or such financing even if obtained may not be adequate for the development of the CPNS System; and that we may not adequately address the lessons learned from the Cardionomic pilot studies which included fatigue to nerves if stimulation is delivered for too long; high amplitude stimulation can lead to unstable hemodynamics, rhythm disturbances, and patient sensation; optimal stimulation response is dependent on more than just contractility; stimulation beyond 48 hours did not show additional benefit; stimulator modifications required to reduce procedure time, complexity, and improve user experience; and minor catheter modifications needed to accommodate larger anatomy in heart failure patients. FDA review of the CPNS System is likely to be costly and lengthy, and there is no guarantee that clearance and approval will ever occur or occur on a timetable that is beneficial to the Company. Additionally, the new subsidiary has other, minority investors aside from the Company, and future financings are expected to involve the issuance of securities by the subsidiary, which will reduce the Company's share in the profits, if any, from the CPNS System and the new subsidiary, and is likely to involve the grant of special corporate governance rights to other subsidiary investors so that the Company will not have unfettered control of the new subsidiary. There is no guarantee that the success of the pilot studies will be repeated in future trials or ultimately lead to a successful commercialization of the CPNS System. The medical device industry in general is highly competitive, and some of our competitors have longer, more established operating histories, with significantly greater financial, technical, marketing, sales, distribution, and other resources. The CPNS System is not the only device-based neuromodulation therapy currently in development for the treatment of heart failure and further must also compete against potential new drug therapies. In general, results of anticipated trials may not turn out as we currently expect, and future trials may not occur on the timetables we expect or may be more costly than anticipated. In addition, our forward looking statements are subject to the following additional uncertainties and risks: even with this recent financing, we do not have sufficient liquidity to fund our business unless we are able to obtain additional financing or enter into a strategic transaction that would provide additional liquidity during the next three to six months will not be able to reach profitability unless we are able to achieve our product expansion and growth goals, our research and development and commercialization efforts may depend on entering into agreements with corporate collaborators, we have in the past entered into joint marketing agreements with respect to our products, and may again enter into additional joint marketing agreements in the future that could reduce our revenues from product sales, if we experience significant disruptions in our information technology systems, our business may be adversely affected, litigation and other legal proceedings may adversely affect our business, if we make acquisitions or divestitures, we could encounter difficulties that harm our business, failure to attract and retain sufficient qualified personnel could also impede our growth, failure to maintain effective internal controls could cause our investors to lose confidence in us and adversely affect the market price of our common stock, we have determined that our internal controls and disclosure controls were not effective as of March 31, 2024, June 30, 2024, September 30, 2024, and December 31, 2024, and as a result, without effective remediation of the material weaknesses that we have identified, we may not be able to accurately report our financial results or prevent fraud, our revenues may depend on our customers' receipt of adequate reimbursement from private insurers and government sponsored healthcare programs, we may be unable to compete successfully with companies in our highly competitive industry, many of whom have substantially greater resources than we do, our future operating results depend upon our ability to obtain components in sufficient quantities on commercially reasonable terms or according to schedules, prices, quality and volumes that are acceptable to us, and suppliers may fail to deliver components, or we may be unable to manage these components effectively or obtain these components on such terms, if hospitals, physicians and patients do not accept our current and future products or if the market for indications for which any product candidate is approved is smaller than expected, we may be unable to generate significant revenue, if any, our medical device operations are subject to pervasive and continuing FDA regulatory requirements, our products may be subject to additional recalls, revocations or suspensions after receiving FDA or foreign approval or clearance, which could divert managerial and financial resources, harm our reputation, and adversely affect our business, changes in trade policies among the U.S. and other countries, in particular the imposition of new or higher tariffs by the U.S. and/or its trading partners could increase our expenses, require us to increase prices, potentially lowering demand for our products, and/or reduce our revenues and operating results, and such increase , or the imposition of other barriers to international trade, could have a material adverse effect on our revenues and operating results. The risks and uncertainties described above may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty, or other pandemics, supply chain disruptions from the Ukraine war or Israeli-Hamas conflict and otherwise, and ongoing volatility in the stock markets and the U.S. economy in general. The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law. CONTACTS: At the CompanyDavid Jenkins973-691-2000info@ # # #Sign in to access your portfolio
CBC
07-05-2025
- CBC
Former P.E.I. chief justice to lead school review in wake of former substitute's sex charges
Former chief justice of P.E.I. Supreme Court named to handle review of PSB's handling of complaints 4 hours ago Duration 4:29 P.E.I.'s former chief justice David Jenkins (shown) will lead a review looking at policies and procedures in Island schools to protect students from sexual predators. This, after a former substitute teacher pleaded guilty last week to sexual interference, in a case involving an elementary school student. CBC's Kerry Campbell reports. WARNING: This story contains descriptions of child sex abuse and other content that may be disturbing to readers. The P.E.I. government has appointed a former provincial chief justice to lead a review of policies and procedures in Island schools to protect students from sexual predators. In the legislature Tuesday, Education Minister Robin Croucher said David Jenkins will head up that third-party review of the Public Schools Branch and its practices. The inquiry comes after a former substitute teacher pleaded guilty last week to sexual interference in a case involving an elementary student. "We're going to be looking at the policies and procedures and figuring out where they need to be strengthened so that we can protect our students moving forward [and] give our educators the tools and the education and the knowledge to implement the policies and procedures," Croucher said after question period. The system did fall down somewhere along the way, and how serious that is, how significant that was will be determined in this investigation. "The system did fall down somewhere along the way, and how serious that is, how significant that was will be determined in this investigation." Matthew Alan Craswell, 40, was first charged last summer with possession and distribution of child pornography after the U.S.-based National Center for Missing and Exploited Children flagged his internet activity. New information came to light during the RCMP investigation, details of which were shared in court last week as Craswell pleaded guilty to four charges related to child sex abuse images and an unrelated incident in which he sexually touched a young girl in a classroom in front of other students at a Stratford primary school. Court documents indicate school officials were made aware of the primary school incident, but it was not reported to police. Craswell continued to work in schools with older children after the Public Schools Branch was informed. He worked as a substitute teacher on P.E.I. as recently as the spring of 2024. This government has an obligation to answer questions from parents who are really scared about the safety of their children. On Tuesday, Croucher gave his Education Department credit for moving "swiftly" in ordering the third-party review. But the Opposition said it's not moving fast enough, given Craswell's activities took place over a two-year period. Hal Perry, the interim Liberal leader, said the province needs to order an investigation, not just a review of Public Schools Branch policies. "This government has an obligation to answer questions from parents who are really scared about the safety of their children in the school system and how this could possibly have happened," Perry said. "Maybe other cases have happened that [they're] not even aware of — and they want to prevent it from ever happening again." While the province is still drawing up terms of reference for the review, Croucher said Jenkins will have the power to compel documents and witnesses, much as he would in a public inquiry. There are questions around: why the Public Schools Branch allowed Craswell to continue teaching after allegations were brought up twice; why school officials didn't initially notify police; and whether it was possible for a vulnerable sector check conducted by the RCMP to turn up a 2018 extradition order from South Korea for Craswell regarding voyeurism allegations in that country. Jenkins's review will begin June 2, and the province said the final report will be made public. Croucher has committed to implementing any recommendations that come out of it as quickly as possible. "I do not believe there was any [malicious] intent by any member of our education system in this situation," he said. "But if there was, it will be investigated, it will be uncovered and it will be dealt with."
